OncoMatch/Clinical Trials/NCT07763301
YMN-136 Vaccine for Patients With Advanced Hepatobiliary and Pancreatic Malignancies
Is NCT07763301 recruiting? Yes, currently enrolling (Sep 2026). This Phase 1 trial studies YMN-136 vaccine for liver cancer.
Treatment: YMN-136 vaccine — This study aims to determine the safety and maximum tolerated dose (MTD) of YMN-136 vaccine through a dose escalation trial, and to investigate whether YMN-136 vaccine can assist in the treatment of patients with advanced hepatobiliary and pancreatic malignancies.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Hepatocellular Carcinoma
Pancreatic Cancer
Cholangiocarcinoma
Biomarker criteria
Required: IMP3 expression (positive)
Positive IMP3 expression
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Must have received: PD-(L)1 inhibitor — advanced hepatocellular carcinoma
disease progression after prior treatment with PD-(L)1 and mTKI systemic therapy (either separately or in combination)
Must have received: multi-targeted tyrosine kinase inhibitor — advanced hepatocellular carcinoma
disease progression after prior treatment with PD-(L)1 and mTKI systemic therapy (either separately or in combination)
Must have received: gemcitabine-containing systemic therapy — advanced biliary tract cancer
disease progression after prior treatment with gemcitabine-containing systemic therapy and non-cytotoxic therapy (i.e., targeted therapy or immunotherapy)
Must have received: non-cytotoxic therapy (targeted therapy or immunotherapy) — advanced biliary tract cancer
disease progression after prior treatment with gemcitabine-containing systemic therapy and non-cytotoxic therapy (i.e., targeted therapy or immunotherapy)
Must have received: systemic therapy (fluoropyrimidines and gemcitabine required) — advanced pancreatic cancer
disease progression after prior treatment with at least two systemic therapies (must include fluoropyrimidines and gemcitabine)
Cannot have received: vaccine therapy
Prior receipt of vaccine therapy
Lab requirements
Blood counts
ANC ≥ 1.5 × 10⁹/L; Platelet count ≥ 75 × 10⁹/L; Hemoglobin ≥ 90 g/L
Kidney function
Serum creatinine ≤ 1.5 × ULN, or creatinine clearance ≥ 45 mL/min
Liver function
Total bilirubin ≤ 1.5 × ULN; ALT and AST ≤ 2.5 × ULN, or ≤ 5 × ULN in patients with liver metastases
Cardiac function
QTc interval ≤ 450 ms for males and ≤ 470 ms for females; left ventricular ejection fraction ≥ 50%
Organ function levels at screening must meet the following requirements: ... (see full text for details)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT07763301 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior vaccine therapy disqualifies patients from enrollment.
Does this trial require IMP3?
Yes, IMP3 expression is a required biomarker for enrollment.
Is there an age limit?
Yes. Patients must be 75 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify